Cancer immunotherapy is employed by blocking the multiple negative regulatory proteins of T-cell activation known as cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), programmed death-ligand 1 (PD-L1), and programmed death 1 (PD1) [66]. Here, CTLA4 is linked to cancer.